02:07

Tiffany: A Multiple Myeloma Patient Tells her clonoSEQ® MRD Testing Story (2 Minute version)

01:14

Tiffany: A Multiple Myeloma Patient Tells her clonoSEQ® MRD Testing Story (60 second version)

02:33

The critical role of minimal residual disease (MRD) throughout the cancer care journey 1080p

02:09

Karen: Multiple Myeloma Patient Discusses clonoSEQ® MRD Testing (2 Minute version)

01:06

Karen: Multiple Myeloma Patient Discusses clonoSEQ® MRD Testing

01:23

The Impact of Women in Leadership

00:58

clonoSEQ® patient Steve, who has multiple myeloma

00:50

Steve, a multiple myeloma patient, and the value of MRD testing

01:01:59

Highlights from Some of the ASH 2021 MRD Data

01:04

Tim: Myeloma Patient Discusses MRD Testing

01:04

Lee: CLL Patient Discusses MRD Testing

36:21

Adaptive Biotechnologies Product Theater presented at ASH 2021

01:09

Surrounded by a World of Science

01:33

We’re Learning to Do What the Adaptive Immune System Knows How to Do

01:06

A Never-ending Amount of Excitement

02:33

clonoSEQ: What is MRD

03:06

Adaptive's New Headquarters

01:41

Introducing Adaptive

01:10

Introducing the Adaptive A

09:43

How Understanding T Cells Could Change Medicine

30:46

ASCO 2021 clonoSEQ Industry Expert Theater

02:07

immunoSEQ® Mouse TCRB Assay Case Study Video

06:32

MRD Helps Predict Outcomes and Informs Transplant Decision for an ALL Patient

08:06

MRD Helps Predict Outcomes and Informs Treatment Decision for a Myeloma Patient

01:02:22

COVID-19 T-Cell Data: Mapping Out SARS- CoV-2 Antigen & T-Cell Repertoires

06:01

Individualizing Transplant Decisions Based on Depth of Response in Myeloma

05:42

Initiating Consolidation Prior to Transplant Based on MRD Positivity in Acute Lymphoblastic Leukemia

04:19

MRD to Assess Response and Inform Transplant Decision in a Relapsed ALL Patient

07:24

MRD Helps Predict Outcomes and Informs Transplant Decision for an ALL Patient

06:19

MRD to Motivate a Myeloma Patient to Augment Therapy

05:46

MRD to Assess Depth of Response in a High-Risk Myeloma Patient

06:03

MRD-Based Risk Assessment in Multiple Myeloma to Inform Maintenance Discontinuation

05:33

MRD-Informed Treatment Decisions in a Patient with Relapsed Myeloma

09:20

MRD to Support Treatment Planning in a Young, High-Risk ALL Patient

09:35

MRD Helps Predict Outcomes and Informs Maintenance Treatment for a Myeloma Patient

48:03

ASH 2020 Product Theater: Lanny Kirsch, MD

02:11

Adaptive Virtual Office Tour

01:37

Adaptive Biotechnologies' Immune Medicine Platform / We've Arrived

02:33

What is NGS MRD?

03:03

The Power of Immunosequencing

02:14

The Adaptive Immune System: A Primer

02:11

Adaptive Biotechnologies’ Immune Medicine Platform

02:45

Pioneers in Immune Medicine

01:52

ImmuneCODE Chapter 2 – The immune response timeline for T cells and antibodies

01:13

ImmuneCODE Chapter 1 – What the immune response can tell us about relevant antigens

01:37

So Many Opportunities to Grow

01:15

ImmuneCODE Chapter 3 – A T-cell signature for COVID-19 diagnostics